Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00-100.00%Company Profile
- CEO
- Lisa McGrath
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 1.75
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.63
Financials
Revenue
$0.00-100.0%Net Income
$-28.19MEBITDA
$-23.09MFree Cash Flow
$-19.54MEPS (diluted)
$-0.46Shares Outstanding (diluted)
60.72M+214.0%Operating Expenses
$22.41MCash & Debt
$56.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $30.00M | $-65.30M | $-1.17 |
| 2021 | $2.69M | $-79.46M | $-1.80 |
| 2020 | $126.16M | $59.34M | $1.67 |
| 2019 | $15.36M | $-53.00M | $-1.90 |
| 2018 | $59.42M | $-6.60M | $-0.33 |
| 2017 | $12.83M | $-45.38M | $-2.35 |
| 2016 | $6.63M | $-17.45M | $-0.90 |
Valuation
SURFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
73-18.52%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·29d ago·Negative
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near-term binary risk and opportunity for the company. Company's SNAP platform enables selective FGFR3 targeting, aiming to address efficacy and tolerability gaps left by pan-FGFR inhibito…
View source ↗ - Newsprnewswire.com·32d ago·Neutral
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, Septemb…
View source ↗ - Newsseekingalpha.com·57d ago·Negative
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. However, if they succeed with that trial, I believe it would also help TYRA's broader SNAP drug-design platform. In that sense, a strong, complete-response signal with a good safety profile could de-risk dabogratinib and improve TYRA's risk-reward profile as a whole.
View source ↗
Earnings
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 1$-0.39 vs $-0.36miss
- Wed, Aug 2$0.41 vs $0.34beat
- Thu, May 4$0.33 vs $0.37miss
- Thu, Mar 9$0.35 vs $0.27beat
- Wed, Nov 2$0.39 vs $0.46miss
Estimates and results for SURF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SURF officers and directors.
- Bought
- —
- Sold
- $3.5m
0 trades
17 trades
- Adams Chandrasold
- Fees Jessicasold
- Oneill Alisonsold
- Ross Robert W.sold
- Rath Henry C.sold
- Oneill Alisonsold
- Ross Robert W.sold
- Fees Jessicasold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SURF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.